REPL - Replimune cut to Underweight at J.P. Morgan on further headline risk
2025-09-19 11:17:20 ET
More on Replimune Group
- Replimune Group: The Prospects For FDA Approval After Rejection
- Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
- Replimune down amid uncertainty over accelerated approval
- Replimune gains as FDA to discuss path for rejected skin cancer drug
- Seeking Alpha’s Quant Rating on Replimune Group